[Effects of anti-androgens on sexual function. Double-blind comparative studies on allylestrenol and chlormadinone acetate Part I: Nocturnal penile tumescence monitoring].
Allylestrenol (ALE) and chlormadinone acetate (CMA) were administered to patients with prostatomegaly by the double-blind method, and the effects of these antiandrogens on their sexual function were objectively compared. Each agent was orally administered to 58 patients in a dosage of 50 mg/day for 12 consecutive weeks. For the objective evaluation of the sexual function, nocturnal penil tumescence (NPT) was measured using an erectometer. For the subjective evaluation the conventional interview method was employed. The levels of hormones relating to sexual function were also determined. A decrease in NPT was noted in both the ALE and CMA groups, but the degree of the decrease was significantly smaller in the ALE group than in the CMA group (p less than 0.001). The results of the interview, revealed a large between the two drug groups; in the CMA group, marked worsening for all items. In the determination of hormones, levels of luteinizing hormone, follicle stimulating hormone, testosterone and estradiol were decreased in both drug groups, while the prolactin level was increased in both groups. The changes in the testosterone, estradiol and prolactin levels in the CMA group were significantly dominant compared with those in the ALE group. In addition, drop-out cases due to a decrease in the sexual function numbered 7 (12.1%) in the CMA group, while there were no such drop-out cases in the ALE group; the difference in the drop-out rate was thus significant. In conclusion, ALE's effects on the sexual function were concluded to be smaller than those of CMA.
Department of Urology, Sapporo Medical College.
Y
Y
Kumamoto
Y
Y
Yamaguchi
Y
Y
Sato
R
R
Suzuki
H
H
Tanda
S
S
Kato
K
K
Mori
H
H
Matsumoto
A
A
Maki
M
M
Kadono
D000368:Aged; D000500:Allylestrenol / Q000494:pharmacology* / Q000627:therapeutic use; D002715:Chlormadinone Acetate / Q000494:pharmacology* / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D004963:Estrenes / Q000494:pharmacology*; D006801:Humans; D008297:Male; D008875:Middle Aged; D008991:Monitoring, Physiologic / Q000379:methods*; D015337:Multicenter Studies as Topic; D010410:Penile Erection / Q000187:drug effects / Q000502:physiology*; D011470:Prostatic Hyperplasia / Q000097:blood / Q000188:drug therapy / Q000503:physiopathology*; D012890:Sleep / Q000502:physiology*; D013739:Testosterone / Q000097:blood; D014554:Urination / Q000187:drug effects
D004963:Estrenes; D002715:Chlormadinone Acetate; D013739:Testosterone; D000500:Allylestrenol